Back to Search
JOE WISEMAN, M.D.
M.D.
Otolaryngology/Facial Plastic Surgery Physician
NPI: 1205819497Individual
Specialties, Licenses & Credentials
Otolaryngology/Facial Plastic Surgery PhysicianPrimary
Otolaryngology — Otolaryngology/Facial Plastic Surgery
Code: 207YX0905X
K1133(TX)
Research & Publications (20)
Desorption electrospray ionization mass spectrometry: Imaging drugs and metabolites in tissues.
PMID 18697929·Proc Natl Acad Sci U S A·2008
7-preclinical
Recent patents regarding the discovery of small molecule CXCR4 antagonists.
PMID 19441896·Expert Opin Ther Pat·2009
6-review
Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation approach.
PMID 19523822·Bioorg Med Chem Lett·2009
8-other
Grand canonical free-energy calculations of protein-ligand binding.
PMID 19309088·J Chem Inf Model·2009
8-other
Fragment-based computation of binding free energies by systematic sampling.
PMID 19610599·J Chem Inf Model·2009
8-other
Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
PMID 19656678·Bioorg Med Chem Lett·2009
7-preclinical
Cryptococcus neoformans directly stimulates perforin production and rearms NK cells for enhanced anticryptococcal microbicidal activity.
PMID 19307209·Infect Immun·2009
8-other
In contrast to anti-tumor activity, YT cell and primary NK cell cytotoxicity for Cryptococcus neoformans bypasses LFA-1.
PMID 19261694·Int Immunol·2009
8-other
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
PMID 19520573·Bioorg Med Chem Lett·2009
7-preclinical
Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
PMID 19195882·Bioorg Med Chem Lett·2009
4-observational
Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy.
PMID 19171478·Eur J Cancer·2009
8-other
The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
PMID 19498103·J Pharmacol Exp Ther·2009
7-preclinical
Climate transformation: the next revolution in public health?
PMID 18845689·J Public Health (Oxf)·2008
8-other
The current state of musculoskeletal clinical skills teaching for preclerkship medical students.
PMID 18925682·J Rheumatol·2008
8-other
Late expression of granulysin by microbicidal CD4+ T cells requires PI3K- and STAT5-dependent expression of IL-2Rbeta that is defective in HIV-infected patients.
PMID 18490721·J Immunol·2008
8-other
Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
PMID 18539455·Bioorg Med Chem Lett·2008
7-preclinical
Palifermin mediates immunoregulatory effects in addition to its cytoprotective effects in mice with acute graft-versus-host disease.
PMID 18592360·J Clin Immunol·2008
7-preclinical
Community wellbeing in an unwell world: trends, challenges, and possibilities.
PMID 18701903·J Public Health Policy·2008
8-other
Hope, despair and transformation: Climate change and the promotion of mental health and wellbeing.
PMID 18799005·Int J Ment Health Syst·2008
8-other
Transantral endoscopic repair of orbital floor fractures with the use of a flexible endoscope holder: a cadaver study.
PMID 19105145·Ear Nose Throat J·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- LANDSTUHL REGIONAL MEDICAL CENTER, 12 C ENT CLINIC
APO, AE 09180 - Phone
- 011496371
Quick Facts
- NPI
- 1205819497
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile